ECSP22001370A - Inhibidores de prmt5 - Google Patents
Inhibidores de prmt5Info
- Publication number
- ECSP22001370A ECSP22001370A ECSENADI20221370A ECDI202201370A ECSP22001370A EC SP22001370 A ECSP22001370 A EC SP22001370A EC SENADI20221370 A ECSENADI20221370 A EC SENADI20221370A EC DI202201370 A ECDI202201370 A EC DI202201370A EC SP22001370 A ECSP22001370 A EC SP22001370A
- Authority
- EC
- Ecuador
- Prior art keywords
- overexpression
- disorders
- prmt5
- prmt5 inhibitors
- relates
- Prior art date
Links
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 title abstract 3
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000002018 overexpression Effects 0.000 abstract 2
- 229940127073 nucleoside analogue Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La invención se refiere a análogos de nucleósidos sustituidos de fórmula (I), a sales farmacéuticamente aceptables de los mismos y a composiciones farmacéuticas para tratar enfermedades, trastornos o afecciones asociados con la sobreexpresión de la enzima PRMT5. La invención también se refiere a métodos para tratar enfermedades, trastornos o afecciones asociados con la sobreexpresión de la enzima PRMT5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921022972 | 2019-06-10 | ||
| IN201921022971 | 2019-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22001370A true ECSP22001370A (es) | 2022-02-25 |
Family
ID=71670318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI20221370A ECSP22001370A (es) | 2019-06-10 | 2022-01-07 | Inhibidores de prmt5 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US12391695B2 (es) |
| EP (1) | EP3980417B1 (es) |
| JP (1) | JP7686579B2 (es) |
| KR (1) | KR20220019781A (es) |
| CN (1) | CN114026094B (es) |
| AU (1) | AU2020293021B2 (es) |
| BR (1) | BR112021024999A2 (es) |
| CA (1) | CA3141748A1 (es) |
| CL (1) | CL2021003292A1 (es) |
| CO (1) | CO2022000061A2 (es) |
| CR (1) | CR20220010A (es) |
| CY (1) | CY1126537T1 (es) |
| DK (1) | DK3980417T3 (es) |
| EC (1) | ECSP22001370A (es) |
| ES (1) | ES2967457T3 (es) |
| FI (1) | FI3980417T3 (es) |
| HR (1) | HRP20231673T1 (es) |
| HU (1) | HUE064493T2 (es) |
| IL (1) | IL288401A (es) |
| LT (1) | LT3980417T (es) |
| MX (1) | MX2021015262A (es) |
| PE (1) | PE20230245A1 (es) |
| PH (1) | PH12021553082A1 (es) |
| PL (1) | PL3980417T3 (es) |
| PT (1) | PT3980417T (es) |
| RS (1) | RS64972B1 (es) |
| SI (1) | SI3980417T1 (es) |
| SM (1) | SMT202400014T1 (es) |
| WO (1) | WO2020250123A1 (es) |
| ZA (1) | ZA202109573B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4069698A1 (en) * | 2019-12-03 | 2022-10-12 | Lupin Limited | Substituted nucleoside analogs as prmt5 inhibitors |
| WO2022271540A1 (en) * | 2021-06-21 | 2022-12-29 | Mayo Foundation For Medical Education And Research | Inhibitors of dot1l |
| US20240368153A1 (en) * | 2021-07-02 | 2024-11-07 | Mirati Therapeutics, Inc. | Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| CN121925419A (zh) * | 2023-09-06 | 2026-04-24 | 赛诺哈勃药业(成都)有限公司 | 一种吡啶-2(1h)-酮类prmt5-mta抑制剂、其药物组合物及其应用 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| FR3161349B1 (fr) * | 2024-04-17 | 2026-04-10 | Univ Sorbonne | Nouveaux inhibiteurs des transporteurs de cations organiques pour le traitement des troubles de l’humeur |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57163383A (en) * | 1980-12-12 | 1982-10-07 | Toyo Jozo Co Ltd | Neplanocin a derivative |
| US4975434A (en) * | 1986-05-27 | 1990-12-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antiviral and anticancer cyclopentenyl cytosine |
| ATE336492T1 (de) * | 2000-01-14 | 2006-09-15 | Us Gov Health & Human Serv | Methonocarbacycloalkylanaloga von nucleosiden |
| WO2006091905A1 (en) | 2005-02-25 | 2006-08-31 | Gilead Sciences, Inc. | Bicyclo (3.1.0) hexane derivatives as antiviral compounds |
| TWI412322B (zh) | 2005-12-30 | 2013-10-21 | 杜邦股份有限公司 | 控制無脊椎害蟲之異唑啉 |
| AR064415A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
| WO2009074487A1 (en) | 2007-12-11 | 2009-06-18 | F. Hoffmann-La Roche Ag | Inhibitors of stearoyl-coa desaturase |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| AR074024A1 (es) | 2008-11-14 | 2010-12-15 | Merial Ltd | Compuesto de arilazol-2-il-cianoetilamino enantiomericamente enriquecidos, composicion plaguicida y su uso para prevenir la infeccion parasitaria |
| GB0922332D0 (en) | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
| WO2011079236A1 (en) | 2009-12-22 | 2011-06-30 | The Ohio State University Research Foundation | Compositions and methods for cancer detection and treatment |
| JP5744021B2 (ja) | 2010-06-30 | 2015-07-01 | 富士フイルム株式会社 | 新規なニコチンアミド誘導体またはその塩 |
| WO2012037108A1 (en) | 2010-09-13 | 2012-03-22 | Glaxosmithkline Llc | Aminoquinoline derivatives as antiviral agents |
| CN103221410B (zh) | 2010-09-22 | 2017-09-15 | 艾尼纳制药公司 | Gpr119受体调节剂和对与其相关的障碍的治疗 |
| CN104662018B (zh) * | 2012-04-20 | 2017-10-24 | 阿迪维纳斯治疗有限公司 | 取代的杂双环化合物、组合物及其医疗应用 |
| US10118918B2 (en) | 2012-12-21 | 2018-11-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム,インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するprmt5阻害剤およびその使用 |
| US9604930B2 (en) | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
| US9908887B2 (en) | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| US9365555B2 (en) | 2012-12-21 | 2016-06-14 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| GB201302927D0 (en) | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| JP6510485B2 (ja) | 2013-03-15 | 2019-05-08 | オハイオ・ステイト・イノベーション・ファウンデーション | Prmt5インヒビターおよびそれらの使用方法 |
| MX380928B (es) | 2013-10-10 | 2025-03-12 | Araxes Pharma Llc | Inhibidores de kras g12c. |
| EP3160466A4 (en) | 2014-06-25 | 2017-12-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| DK3160958T3 (da) | 2014-06-25 | 2021-04-12 | Glaxosmithkline Ip Dev Ltd | Krystallinske salte af (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidin-4-carboxamid |
| WO2015200680A2 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| AU2015301196A1 (en) | 2014-08-04 | 2017-01-12 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| US10005792B2 (en) | 2014-09-03 | 2018-06-26 | Ctxt Pty. Ltd. | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors |
| US10494376B2 (en) | 2014-09-03 | 2019-12-03 | Ctxt Pty. Ltd. | Tetrahydroisoquinoline derived PRMT5-inhibitors |
| GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| WO2016038550A1 (en) | 2014-09-11 | 2016-03-17 | Novartis Ag | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
| EA031895B1 (ru) | 2015-02-24 | 2019-03-29 | Пфайзер Инк. | Замещенные нуклеозидные производные, полезные в качестве агентов против рака |
| US20180271891A1 (en) | 2015-03-11 | 2018-09-27 | The Broad Institute Inc. | Selective treatment of prmt5 dependent cancer |
| AR104326A1 (es) | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
| TWI730980B (zh) * | 2015-08-26 | 2021-06-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| TW201722957A (zh) | 2015-09-15 | 2017-07-01 | 葛蘭素史克智慧財產(第二)有限公司 | 化學化合物 |
| WO2017100716A1 (en) | 2015-12-11 | 2017-06-15 | Eaton Corporation | Autonomous dock |
| CA2969295A1 (en) | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
| WO2018065365A1 (en) * | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| WO2018085818A1 (en) | 2016-11-07 | 2018-05-11 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018152548A1 (en) * | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018152501A1 (en) | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018160824A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018167800A1 (en) | 2017-03-13 | 2018-09-20 | Impetis Biosciences Limited | Fused bicyclic compounds, compositions and applications thereof |
| CR20200263A (es) * | 2017-12-13 | 2020-07-26 | Lupin Ltd | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 |
| EP4069698A1 (en) * | 2019-12-03 | 2022-10-12 | Lupin Limited | Substituted nucleoside analogs as prmt5 inhibitors |
-
2020
- 2020-06-09 CR CR20220010A patent/CR20220010A/es unknown
- 2020-06-09 CA CA3141748A patent/CA3141748A1/en active Pending
- 2020-06-09 MX MX2021015262A patent/MX2021015262A/es unknown
- 2020-06-09 WO PCT/IB2020/055401 patent/WO2020250123A1/en not_active Ceased
- 2020-06-09 DK DK20742922.6T patent/DK3980417T3/da active
- 2020-06-09 ES ES20742922T patent/ES2967457T3/es active Active
- 2020-06-09 FI FIEP20742922.6T patent/FI3980417T3/fi active
- 2020-06-09 PL PL20742922.6T patent/PL3980417T3/pl unknown
- 2020-06-09 SM SM20240014T patent/SMT202400014T1/it unknown
- 2020-06-09 BR BR112021024999A patent/BR112021024999A2/pt unknown
- 2020-06-09 PE PE2021002071A patent/PE20230245A1/es unknown
- 2020-06-09 EP EP20742922.6A patent/EP3980417B1/en active Active
- 2020-06-09 US US17/618,042 patent/US12391695B2/en active Active
- 2020-06-09 PT PT207429226T patent/PT3980417T/pt unknown
- 2020-06-09 KR KR1020227000720A patent/KR20220019781A/ko not_active Withdrawn
- 2020-06-09 HR HRP20231673TT patent/HRP20231673T1/hr unknown
- 2020-06-09 JP JP2021573236A patent/JP7686579B2/ja active Active
- 2020-06-09 PH PH1/2021/553082A patent/PH12021553082A1/en unknown
- 2020-06-09 RS RS20231219A patent/RS64972B1/sr unknown
- 2020-06-09 SI SI202030344T patent/SI3980417T1/sl unknown
- 2020-06-09 HU HUE20742922A patent/HUE064493T2/hu unknown
- 2020-06-09 LT LTEPPCT/IB2020/055401T patent/LT3980417T/lt unknown
- 2020-06-09 AU AU2020293021A patent/AU2020293021B2/en active Active
- 2020-06-09 CN CN202080042550.3A patent/CN114026094B/zh active Active
-
2021
- 2021-11-25 ZA ZA2021/09573A patent/ZA202109573B/en unknown
- 2021-11-25 IL IL288401A patent/IL288401A/en unknown
- 2021-12-10 CL CL2021003292A patent/CL2021003292A1/es unknown
-
2022
- 2022-01-06 CO CONC2022/0000061A patent/CO2022000061A2/es unknown
- 2022-01-07 EC ECSENADI20221370A patent/ECSP22001370A/es unknown
-
2023
- 2023-12-21 CY CY20231100771T patent/CY1126537T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022000061A2 (es) | Inhibidores de prmt5 | |
| CL2020001576A1 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5. | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| BR112021022457A2 (pt) | Inibidores de fgfr e métodos de uso dos mesmos | |
| CY1126110T1 (el) | Παραγωγα βενζοϋδροξαμικου οξεος ως εκλεκτικοι αναστολε1σ του hdac6 | |
| EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
| BR112021018664A2 (pt) | Inibidores de proteína tirosina fosfatase | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| BR112021020285A2 (pt) | Métodos e composições para degradação de proteína alvejada | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| EA201891703A1 (ru) | Соединения бензопиразола и их аналоги | |
| CO2019010559A2 (es) | Composiciones y compuestos terapéuticos y métodos para utilizarlos | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| NO20076093L (no) | Substituerte amidderivater som proteinkinaseinhibitorer | |
| EA202091016A1 (ru) | Пиримидиновое соединение в качестве ингибитора jak киназы | |
| MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
| MX2022006735A (es) | Análogos de nucleósidos sustituidos como inhibidores de la prmt5. | |
| MX394700B (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos. | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
| CO2021001277A2 (es) | Inhibidores de triazol glicolato oxidasa | |
| BR112022003584A2 (pt) | Compostos de pirrolopirimidina inibidores de perk | |
| UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
| MX2022002443A (es) | Compuestos inhibidores de perk. |